Your browser is no longer supported. Please, upgrade your browser.
Settings
FOLD Amicus Therapeutics, Inc. daily Stock Chart
FOLD [NASD]
Amicus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own1.00% Shs Outstand140.73M Perf Week1.13%
Market Cap882.38M Forward P/E- EPS next Y-1.18 Insider Trans-34.53% Shs Float140.57M Perf Month16.76%
Income-184.30M PEG- EPS next Q-0.33 Inst Own97.60% Short Float23.32% Perf Quarter-28.67%
Sales2.10M P/S420.18 EPS this Y-29.80% Inst Trans-0.39% Short Ratio9.09 Perf Half Y-10.56%
Book/sh2.39 P/B2.62 EPS next Y15.70% ROA-20.50% Target Price11.06 Perf Year-7.39%
Cash/sh1.51 P/C4.15 EPS next 5Y35.00% ROE-55.40% 52W Range4.41 - 9.83 Perf YTD26.16%
Dividend- P/FCF- EPS past 5Y9.50% ROI- 52W High-36.22% Beta1.64
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin83.80% 52W Low42.18% ATR0.31
Employees185 Current Ratio2.60 Sales Q/Q- Oper. Margin- RSI (14)66.36 Volatility4.48% 5.29%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.20% Profit Margin- Rel Volume0.64 Prev Close6.08
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 BMO Payout- Avg Volume3.61M Price6.27
Recom1.60 SMA209.54% SMA5013.61% SMA200-4.57% Volume2,305,239 Change3.13%
Jan-24-17Upgrade Robert W. Baird Neutral → Outperform $7 → $10
May-18-16Initiated BofA/Merrill Buy $10
Apr-14-16Initiated Robert W. Baird Neutral $9
Apr-12-16Reiterated Chardan Capital Markets Buy $10 → $15
Sep-16-15Downgrade Chardan Capital Markets Buy → Neutral $17
Jun-16-15Reiterated Chardan Capital Markets Buy $14 → $17.50
May-29-15Initiated Chardan Capital Markets Buy $14
Dec-20-12Reiterated Canaccord Genuity Buy $11 → $6
Dec-20-12Downgrade Capstone Investments Buy → Hold $3
Nov-01-12Initiated Capstone Investments Buy $7
Apr-06-10Initiated Canaccord Adams Buy
Mar-31-10Initiated Leerink Swann Mkt Perform
Oct-05-09Downgrade Wedbush Morgan Outperform → Underperform $17 → $3.50
Mar-20-09Initiated Wedbush Morgan Buy $17
Feb-27-09Reiterated Lazard Capital Buy $18 → $15
Jul-23-08Reiterated Lazard Capital Buy $13 → $21
May-14-08Reiterated Lazard Capital Buy $15 → $13
Jan-04-08Reiterated Lazard Capital Buy $18 → $15
Nov-08-07Reiterated Lazard Capital Buy $20 → $22
Jul-10-07Initiated Pacific Growth Equities Buy
Feb-16-17 07:17AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-15-17 07:30PM  Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium 2017 GlobeNewswire
12:49PM  Amicus Therapeutics Updates Migalastat Drug at Investopedia
08:42AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium 2017 GlobeNewswire
Feb-14-17 07:30PM  Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium 2017 GlobeNewswire
Feb-09-17 04:03PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-06-17 07:30AM  Amicus Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Jan-24-17 09:26AM  Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo
07:30AM  Amicus Therapeutics Announces Presentations and Posters at 13th Annual WORLDSymposium 2017 GlobeNewswire
06:48AM  Amicus Therapeutics upgraded by Robert W. Baird
Jan-09-17 07:30AM  Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance GlobeNewswire
07:08AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,
Jan-08-17 10:10AM  Huge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix, Amicus Therapeutics and More
Jan-04-17 07:30AM  National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for Galafold (migalastat) for Fabry Disease in England GlobeNewswire +9.75%
Jan-01-17 12:40PM  5 Stocks Insiders Love Right Now
Dec-30-16 04:20PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
Dec-23-16 11:22AM  Trump, Interest Rates And Biotech Investing In 2017 at Forbes +10.15%
07:30AM  Amicus Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-16 04:04PM  Abercrombie, OvaScience Slide Into Thursdays 52-Week Low Club at 24/7 Wall St.
02:02PM  Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes at Insider Monkey
Dec-21-16 05:28PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Def
04:01PM  Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes GlobeNewswire
09:15AM  Today's Reports on Biotech Movers Ariad Pharmaceuticals and Amicus Therapeutics Accesswire
Dec-16-16 04:04PM  Abercrombie & Fitch, Hanesbrands Dip into Fridays 52-Week Low Club at 24/7 Wall St.
06:03AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-15-16 08:45PM  Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes GlobeNewswire -17.95%
11:51AM  Amicus Therapeutics, Inc. (FOLD): Breaking Down The Raise at Insider Monkey
08:42AM  Why Amicus Therapeutics Stock Is Sinking Today at Motley Fool
Dec-14-16 05:12PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:01PM  Amicus Therapeutics Announces Proposed Offering of Convertible Senior Notes GlobeNewswire
11:44AM  ETFs with exposure to Amicus Therapeutics, Inc. : December 14, 2016
Dec-12-16 05:00PM  Hedge Funds Are Betting On James River Group Holdings Ltd (JRVR) at Insider Monkey
Dec-09-16 10:03AM  Is Amicus Therapeutics a Bad-News Buy? at Motley Fool
Dec-08-16 08:36AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease GlobeNewswire
Dec-07-16 02:10AM  Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy? at Insider Monkey
Dec-06-16 04:19PM  The Latest Buzz in Biotech at Motley Fool
Dec-03-16 09:25AM  6 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Dec-01-16 02:28PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amicus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
11:42AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD PR Newswire
11:03AM  ETFs with exposure to Amicus Therapeutics, Inc. : December 1, 2016
Nov-30-16 09:40AM  Amicus Fabry Disease Drug Delayed to 2020 (FOLD) at Investopedia -8.14%
07:35AM  Amicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : November 30, 2016
07:13AM  Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno
Nov-29-16 05:06PM  Amicus Provides Regulatory Update on Fabry Disease Drug -21.75%
04:44PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amicus Therapeutics, Inc. (FOLD) PR Newswire
04:14PM  Biotech Movers And Shakers: Nivalis Therapeutics Inc (NVLS) And Amicus Therapeutics, Inc. (FOLD) at Insider Monkey
03:44PM  FDA Requests Additional Data on Amicus Fabry Disease Treatment
01:35PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Amicus Therapeutics, Inc. Business Wire
01:11PM  Why Amicus Therapeutics Shares Are Crashing 21.8% Today at Motley Fool
Nov-28-16 09:52PM  Futures Flat as Investors Take Profits; Asia Mixed -6.52%
05:25PM  Amicus shares drop 28% after FDA denies quick drug approval at MarketWatch
04:48PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
04:34PM  Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan
04:10PM  Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease GlobeNewswire
Nov-17-16 01:04PM  AMICUS THERAPEUTICS INC Financials
Nov-15-16 12:27PM  Is Redmile Group Right to Bet on Array Biopharma Inc (ARRY), Amicus Therapeutics, Inc. (FOLD) & Two Other Stocks? at Insider Monkey
Nov-11-16 07:30AM  Journal of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study of Migalastat for Patients with Fabry Disease GlobeNewswire
Nov-09-16 12:48PM  ETFs with exposure to Amicus Therapeutics, Inc. : November 9, 2016 +9.89%
Nov-08-16 04:51PM  Biotech Gainers On Tuesday: Amicus Therapeutics, Inc. (FOLD) And Ionis Pharmaceuticals Inc (IONS) at Insider Monkey +6.19%
12:53PM  Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors Q3 Returns; See How Other Investments Performed at Insider Monkey
09:30AM  Amicus 3Q Loss $47M or 32 Cents a Share (FOLD) at Investopedia
07:54AM  Amicus Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FOLD-US : November 8, 2016
Nov-07-16 04:43PM  Edited Transcript of FOLD earnings conference call or presentation 7-Nov-16 1:30pm GMT +21.01%
03:22PM  Here's Why Amicus Therapeutics, Inc. Soared As Much As 20% Despite an Earnings Miss at Motley Fool
08:40AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
08:04AM  Amicus Therapeutics reports 3Q loss
07:30AM  Amicus Therapeutics Announces Third Quarter 2016 Financial Results and Corporate Updates GlobeNewswire
07:07AM  Q3 2016 Amicus Therapeutics Inc Earnings Release - Before Market Open
Nov-01-16 07:30AM  Amicus Therapeutics to Announce Third Quarter 2016 Financial Results on November 7, 2016 GlobeNewswire
Oct-31-16 09:21AM  Genetic Stocks to Watch for Earnings on Nov 1: GILD & More
Oct-28-16 04:26PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits -6.15%
Oct-08-16 09:22AM  Five Cheap Healthcare Stocks Poised to Explode at Insider Monkey
Sep-26-16 04:28PM  3 Biotechs With Potential Big-Time Upside at Motley Fool
Sep-22-16 07:30AM  Amicus Therapeutics to Present at LEERINK Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-14-16 06:05AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-13-16 03:17PM  Amicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016
11:51AM  UPDATE -- Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016 GlobeNewswire
Sep-12-16 07:30AM  Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016 GlobeNewswire +6.74%
Sep-07-16 08:20AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-01-16 07:30AM  Amicus Therapeutics to Present at Robert W. Baird & Co. 2016 Healthcare Conference GlobeNewswire
Aug-31-16 07:30AM  Amicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium GlobeNewswire
Aug-23-16 04:11PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits
Aug-17-16 09:29AM  Biotech Industry on the Upswing after Rocky Start to 2016
Aug-11-16 09:30AM  Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines' +6.85%
06:41AM  Rare disease drug innovation: Amicus CEO
Aug-10-16 06:05PM  UPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease GlobeNewswire
05:18PM  New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease GlobeNewswire
05:02PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-09-16 03:44PM  Edited Transcript of FOLD earnings conference call or presentation 9-Aug-16 12:30pm GMT -8.65%
10:59AM  Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss
07:58AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
07:41AM  Amicus Therapeutics reports 2Q loss
07:30AM  Amicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates GlobeNewswire
07:07AM  Q2 2016 Amicus Therapeutics Inc Earnings Release - Before Market Open
Aug-03-16 07:30AM  Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17 GlobeNewswire
Aug-01-16 04:01PM  Amicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016 GlobeNewswire
Jul-29-16 04:14PM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
Jul-12-16 07:30AM  Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg as Vice President, Regulatory Strategy GlobeNewswire
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson's disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Do HungChief Science OfficerFeb 07Sale6.0025,000150,000534,266Feb 09 04:35 PM
Do HungChief Science OfficerJan 13Sale6.0025,000150,000559,266Jan 17 04:14 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 30Buy4.9694,750470,05516,293,847Jan 04 02:25 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 29Buy4.8594,750459,91716,293,847Dec 30 08:45 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 28Buy4.9147,375232,70616,199,097Dec 30 08:45 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 23Buy4.8185,275410,05016,151,722Dec 27 10:57 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 22Buy4.51189,500854,83516,066,447Dec 23 08:31 AM
Quimi DaphneSVP, FinanceNov 09Option Exercise8.002,85822,86427,047Nov 10 04:07 PM
Quimi DaphneSVP, FinanceNov 09Sale8.008,54668,36824,189Nov 10 04:07 PM
Do HungChief Science OfficerNov 01Sale7.0025,000175,000533,453Nov 03 04:07 PM
Do HungChief Science OfficerOct 03Sale7.2525,000181,250558,453Oct 04 08:21 PM
Baird William D IIIChief Financial OfficerSep 20Option Exercise8.003,50028,00056,450Sep 22 04:09 PM
Baird William D IIIChief Financial OfficerSep 20Sale8.0020,500164,07535,950Sep 22 04:09 PM
Do HungChief Science OfficerSep 06Sale7.0025,000175,000583,453Sep 08 04:08 PM
PERCEPTIVE ADVISORS LLCNo longer a 10% Owner.Aug 25Sale6.811,100,0007,491,00014,139,444Aug 26 04:30 PM
Do HungChief Science OfficerAug 04Sale7.0025,000175,000608,453Aug 08 04:28 PM
Barth JayChief Medical OfficerAug 04Sale7.0010,45873,20615,000Aug 08 04:28 PM
Barth JayChief Medical OfficerJul 27Sale7.0020,916146,41225,458Jul 29 05:26 PM
Redmile Group, LLC10% OwnerJun 03Buy7.2066,300477,36012,956,446Jun 13 07:11 PM
Rosenberg EllenGeneral Counsel & Corp. SecyJun 02Buy7.6715,000115,05015,000Jun 06 04:08 PM